Answers are grounded in this paper and cite their sources.
BACKGROUND: Lung cancer is a leading cause of cancer-related mortality. While cisplatin is a cornerstone of chemotherapy, metformin (Glucophage) has shown anti-cancer potential. This study investigated the effects of cisplatin and metformin (Glucophage) on non-small cell lung cancer (NSCLC) cells, focusing on their combined impact on apoptosis-related genes and lncRNAs. METHODS: The A549 (NSCLC) and MRC5 (normal fibroblast) cell lines were treated with cisplatin, metformin (Glucophage), or a combination thereof. Cell viability was assessed by MTT assay, and apoptosis was quantified by flow cytometry. Expression of Bax, Bcl-2, Caspase 3, PVT1, and MEG3 was analyzed by qRT-PCR. RESULTS: Both cisplatin and metformin (Glucophage) individually reduced A549 cell viability in a dose-dependent manner. Combination Index (CI) analysis revealed an additive interaction (CI = 0.935) between the two agents. This combination was associated with an upregulation of pro-apoptotic Bax and lncRNA MEG3, and a downregulation of anti-apoptotic Bcl-2 and oncogenic lncRNA PVT1. CONCLUSION: The combination of cisplatin and metformin (Glucophage) exerts an additive cytotoxic effect and induces apoptosis in NSCLC cells in vitro. This effect is associated with a favorable modulation of key apoptosis-regulating genes and lncRNAs. These findings provide a strong rationale for further mechanistic and preclinical investigation of this combination therapy for lung cancer.
No takes yet. Share an insight, caveat, or question.
Soleimanifar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: